cT3N0M0非小细胞肺癌诱导化疗提高完全切除率但未改善生存
本研究基于美国国家癌症数据库2006至2011年cT3N0M0非小细胞肺癌接受肺叶或全肺切除的患者,比较先手术与诱导化疗后手术两种策略。倾向性匹配后,诱导化疗组R0切除率更高(93.1% vs 90.0%,P=0.04),但90天死亡率更高(6.6% vs 3.4%),长期生存无差异。
要点
- 诱导化疗提高R0切除率但未改善长期生存。
- 诱导化疗组90天死亡率更高,需权衡围术期风险。
- cT3N0M0非小细胞肺癌不应常规考虑诱导化疗。
核心结论
- cT3N0M0非小细胞肺癌诱导化疗虽提高R0切除率,但与改善生存无关,不应常规考虑。
研究设计与样本
- 回顾性队列研究,纳入美国国家癌症数据库2006至2011年cT3N0M0非小细胞肺癌接受肺叶或全肺切除的患者共3791例,其中580例(15%)接受诱导化疗。
- 采用倾向性评分匹配生成匹配队列,比较先手术与诱导化疗后手术的短期结局和生存。
主要发现
- 匹配后诱导化疗组更常接受开放手术(87.3% vs 77.8%,P=0.005)。
- 诱导化疗组R0切除率更高(93.1% vs 90.0%,P=0.04),切缘阳性率更低(6.9% vs 10.0%,P=0.03)。
- 诱导化疗组90天死亡率更高(6.6% vs 3.4%),但两组长期生存无差异。
临床怎么用
- 对于cT3N0M0非小细胞肺癌,不应常规推荐诱导化疗,需个体化评估。
- 诱导化疗可能用于追求R0切除,但需警惕90天死亡率升高。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this study was to evaluate outcomes of induction therapy prior to an operation in patients with cT3 non-small-cell lung cancer (NSCLC). METHODS: Patients diagnosed with cT3N0M0 NSCLC from 2006 to 2011 in the National Cancer Database who were treated with lobectomy or pneumonectomy were stratified by treatment strategy: an operation first versus induction chemotherapy. Propensity scores were developed and matched cohorts were generated. Short-term outcomes included margin status, 30- and 90-day mortality rates, readmission and length of stay. Survival analyses using Kaplan-Meier methods were performed on both the unadjusted and propensity matched cohorts. RESULTS: A total of 3791 cT3N0M0 patients were identified for inclusion, of which 580 (15%) were treated with induction chemotherapy. Prior to adjustment, patients treated with induction chemotherapy were younger, had a higher comorbidity burden and were more likely to have private insurance (all P < 0.001). Following matching, patients receiving induction chemotherapy were more likely to subsequently undergo an open procedure (87.3 vs 77.8%, P = 0.005). These patients were more likely to obtain R0 resection (93.1% vs 90.0%, P = 0.04) and were thereby less likely to have positive margins at the time of resection (6.9% vs 10.0%, P = 0.03). Patients who received induction therapy had higher rates of 90-day mortality (6.6% vs 3.4%) but there was no difference in long-term survival between the groups. CONCLUSIONS: Despite yielding increased rates of R0 resection, induction chemotherapy for cT3N0M0 NSCLC is not associated with improved survival and should not be considered routinely. Further studies are warranted to elucidate cohorts that may benefit from induction therapy.
引用
- Anderson KL, Mulvihill MS, Yerokun BA, et al. Induction chemotherapy for T3N0M0 non-small-cell lung cancer increases the rate of complete resection but does not confer improved survival. Eur J Cardiothorac Surg. 2017. PMID: 28402406. doi:10.1093/ejcts/ezx091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。